HP
HBIO icon

Harvey Partners’s Harvard Bioscience HBIO Stock Holding History

Harvey Partners’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-205,000
Closed -$899K – 46
2025
Q3 		$899K Sell
205,000
-9,110
-4% -$43.2K 0.08% 46
2025
Q2 		$950K Sell
214,110
-4,640
-2% -$19.4K 0.09% 42
2025
Q1 		$1.24M Sell
218,750
-49,550
-18% -$634K 0.14% 42
2024
Q4 		$5.66M Sell
268,300
-3,200
-1% -$73.5K 0.63% 39
2024
Q3 		$7.3M Buy
271,500
+15,750
+6% +$464K 0.83% 39
2024
Q2 		$7.29M Hold
255,750
– – 0.88% 35
2024
Q1 		$10.8M Hold
255,750
– – 1.15% 36
2023
Q4 		$13.7M Hold
255,750
– – 1.55% 31
2023
Q3 		$11M Buy
255,750
+3,350
+1% +$155K 1.39% 32
2023
Q2 		$13.9M Sell
252,400
-18,870
-7% -$1.04M 1.69% 31
2023
Q1 		$11.4M Sell
271,270
-19,880
-7% -$590K 1.41% 32
2022
Q4 		$8.06M Buy
291,150
+20
+0% +$493 1.02% 34
2022
Q3 		$7.45M Buy
291,130
+4,630
+2% +$153K 1.09% 28
2022
Q2 		$10.3M Buy
286,500
+63,900
+29% +$2.88M 2.27% 22
2022
Q1 		$13.8M Buy
222,600
+96,100
+76% +$5.68M 3.41% 15
2021
Q4 		$8.92M Buy
126,500
+24,496
+24% +$1.74M 3.62% 11
2021
Q3 		$7.12M Sell
102,004
-7,996
-7% -$636K 5.32% 5
2021
Q2 		$9.16M Hold
110,000
– – 6.35% 2
2021
Q1 		$6.01M Buy
110,000
+10,700
+11% +$520K 4.15% 7
2020
Q4 		$4.26M Buy
99,300
+20,300
+26% +$758K 2.96% 10
2020
Q3 		$2.38M Sell
79,000
-3,550
-4% -$119K 3.09% 12
2020
Q2 		$2.56M Sell
82,550
-88,297
-52% -$2.38M 3.09% 12
2020
Q1 		$3.78M Buy
170,847
+69,677
+69% +$1.89M 3.42% 10
2019
Q4 		$3.09M Buy
101,170
+26,920
+36% +$775K 1.75% 22
2019
Q3 		$2.28M Buy
+74,250
New +$1.85M 1.65% 18

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Harvey Partners's HBIO Position: Q4 2025 in Review

Harvey Partners sold out of Harvard Bioscience (HBIO) in Q4 2025, closing a stake of 205,000 shares — an estimated $899K sold.

Harvey Partners first reported a position in HBIO in Q3 2019 and held it in 25 quarters. The position peaked at $13.9M in Q2 2023. 63 funds tracked by Wall St. Rank hold HBIO as of Q4 2025.

  • Harvey Partners reported no remaining Harvard Bioscience position as of Q4 2025 after selling out during the quarter.
  • Harvey Partners sold 205,000 Harvard Bioscience shares in Q4 2025, an estimated $899K.
  • Harvey Partners first reported a position in Harvard Bioscience in Q3 2019 and held it in 25 quarters.
  • Harvey Partners's Harvard Bioscience position peaked at $13.9M in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2025.

Based on Harvey Partners's 13F filing for Q4 2025, filed 17 Feb 2026.